Aspen Technology, Inc. (AZPN)
AZPN Price and Sentiment
AZPN Latest news
Aspen Technology (AZPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
On Thursday, Aspen Technology Inc. (NASDAQ:AZPN) shares advanced 3.32% after announcing its most recent quarterly results. The company posted its fiscal-first quarter 2022 revenue and earnings Wednesday after markets closed, beating analyst expectations.
Aspen Technology's (AZPN) Q1 performance reflects the positive impact of increases in customer demand.
Aspen Technology Inc (AZPN) CEO Antonio Pietri on Q1 2022 Results - Earnings Call Transcript
BEDFORD, Mass.--(BUSINESS WIRE)--Aspen Technology, Inc. (AspenTech) (NASDAQ: AZPN), a global leader in asset optimization software, today announced financial results for its first-quarter of fiscal year 2022 ended September 30, 2021. “AspenTech's first quarter results reflected a notable improvement in customer demand, particularly among refining customers. While the macro environment remains fluid, we continue to see positive interest from our customers, who recognize the critical value AspenT
The market is underestimating growth prospects at this serial dividend-paying stock.
SINGAPORE & SAN FRANCISCO--(BUSINESS WIRE)-- #retail--Former AspenTech executive Karl Johnsen joins Trax as CFO; former Boston Consulting Group leader, Debbie Simpson, joins board of directors.
"Mad Money" host Jim Cramer said Tuesday investors are getting an "incredible buying opportunity" in Emerson Electric after Wall Street's muted reaction to the company's plans to combine two of its software units with Aspen Technology.
SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations2021-10-18 17:46
NEW YORK , Oct. 18, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 firstname.lastname@example.org Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) in connection with the proposed acquisition of the company by Supernus Pharmaceuticals, Inc. Under the terms of the agreement, ADMS shareholders will receive $8.10 per share in cash, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of ADMS's lead product, GOCOVRI, for each share of ADMS stock that they hold.
Emerson (EMR) to combine its software business with Aspen Technology (AZPN) to form new AspenTech. The company reaffirms its outlook for fiscal 2021.